QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 therapeuticsmd-q2-eps-005-up-from-009-yoy-sales-1000m-up-from-234000k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly earnings of $0.05 per share. This is a 155.56 percent increase over losses of $...

 therapeuticsmd-q1-eps-006-up-from-007-yoy-sales-39300k-up-from-31300k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.06) per share. This is a 14.29 percent increase over losses of $(...

 therapeuticsmd-q3-eps-005-up-from-013-yoy-sales-54700k-up-from-5300k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.05) per share. This is a 61.54 percent increase over losses of $(...

 therapeuticsmd-q2-eps-009-up-from-024-yoy-sales-23400k-down-from-43700k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.09) per share. This is a 62.5 percent increase over losses of $(0...

 therapeuticsmd-q1-eps-007-up-from-024-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.07) per share. This is a 70.83 percent increase over losses of $(...

 therapeuticsmd-q3-eps-013-misses-005-estimate

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0....

 stocks-that-hit-52-week-lows-on-thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

 cantor-fitzgerald-reiterates-neutral-on-therapeuticsmd-maintains-5-price-target

Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and maintains $5 price target.

 therapeuticsmd-q2-eps-024-misses-007-estimate-sales-from-cont-ops-40000k-miss-50000k-estimate

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION